PCR Shows Off Its Clinical Chops

July 31, 2015
PCR Shows Off Its Clinical Chops
Promega, which produces reaction components for PCR-based molecular assays, notes that the quality controls implemented by manufacturers can affect molecular diagnostic assay design and performance. The company adds that as multiplexed assays and panel tests become more common, lot-to-lot reagent consistency will become more important.

MaryAnn Labant

Since its invention by Kary B. Mullis in 1985, the polymerase chain reaction (PCR) has become well established, even routine, in research laboratories. And now PCR is becoming more common in clinical applications, thanks to advances in genomics and the evolution of more sensitive quantitative PCR methodologies. Examples of clinical applications of PCR include point-of-care (POC) molecular tests for bacterial and viral detection, as well as mutation detection in liquid or tumor biopsies for patient stratification and treatment monitoring.

Industry leaders recently participated in a CHI conference that was held in San Francisco. This conference—PCR for Molecular Medicine—encompassed research and clinical perspectives and emphasized advanced techniques and tools for effective disease diagnosis.

To kick off the event, speakers shared their views on POC molecular tests. These tests, the speakers insisted, can provide significant value to healthcare only if they support timely decision making.

For the rest of the story, click here.

×

Oops! Please type your email in the following format: [email protected]

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly
.